| pubmed-article:15507175 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15507175 | lifeskim:mentions | umls-concept:C0278488 | lld:lifeskim |
| pubmed-article:15507175 | lifeskim:mentions | umls-concept:C0332174 | lld:lifeskim |
| pubmed-article:15507175 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:15507175 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
| pubmed-article:15507175 | lifeskim:mentions | umls-concept:C0671970 | lld:lifeskim |
| pubmed-article:15507175 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:15507175 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:15507175 | lifeskim:mentions | umls-concept:C0205088 | lld:lifeskim |
| pubmed-article:15507175 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:15507175 | pubmed:dateCreated | 2004-10-27 | lld:pubmed |
| pubmed-article:15507175 | pubmed:abstractText | The addition of capecitabine to docetaxel on a 3-week schedule resulted in superior response rate, increased time to progression (TTP), and improved overall survival in patients with anthracycline-pretreated metastatic breast cancer (MBC). Because the toxicity profile of weekly docetaxel differs from the standard 21-day docetaxel schedule, we performed a phase I/II trial to test the efficacy and safety of weekly docetaxel in combination with capecitabine given for 14 days every 21 days. The phase I study identified the doses of docetaxel (30 mg/m2 weekly) and capecitabine (900 mg/m2 twice daily on days 1-14 every 21 days) used in phase II. Twenty female patients with measurable or assessable MBC were enrolled. Eighteen patients had previously received anthracyclines; 2 had contraindications to anthracyclines. Patients remained on study for a maximum of eight 3-week cycles or until tumor progression or unacceptable toxicity occurred; response assessments were scheduled after cycle 2, 5, and 8. Seventeen patients were assessed after cycle 2; 3 subjects (18%) had a partial response (PR), 9 had stable disease (53%; SD), and 5 patients (29%) had progressive disease (PD). Ten patients were assessable after cycle 5. Two patients (20%) had a PR, 5 patients (50%) had SD, and 3 patients (30%) had PD. The most common grade 3 toxicities were nail loss (45%), asthenia (30%), and hand-foot syndrome (30%), and toxicities led to study discontinuation in 10 patients. The median time to treatment failure was 10 weeks and median TTP was 26 weeks. The median duration of response was 9 weeks and the median duration of SD was 16 weeks. The median overall survival was 82 weeks. This schedule of weekly docetaxel in combination with day 1-14 capecitabine has activity; however, toxicity discourages the use of this schedule in lieu of the standard docetaxel/capecitabine regimen. | lld:pubmed |
| pubmed-article:15507175 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15507175 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15507175 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15507175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15507175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15507175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15507175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15507175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15507175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15507175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15507175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15507175 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15507175 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:15507175 | pubmed:issn | 1526-8209 | lld:pubmed |
| pubmed-article:15507175 | pubmed:author | pubmed-author:MackeyJohn... | lld:pubmed |
| pubmed-article:15507175 | pubmed:author | pubmed-author:KoskiSheryl... | lld:pubmed |
| pubmed-article:15507175 | pubmed:author | pubmed-author:SmithStephani... | lld:pubmed |
| pubmed-article:15507175 | pubmed:author | pubmed-author:AuHeather-Jan... | lld:pubmed |
| pubmed-article:15507175 | pubmed:author | pubmed-author:SoulieresDeni... | lld:pubmed |
| pubmed-article:15507175 | pubmed:author | pubmed-author:JoyAnil AAA | lld:pubmed |
| pubmed-article:15507175 | pubmed:author | pubmed-author:TonkinKatia... | lld:pubmed |
| pubmed-article:15507175 | pubmed:author | pubmed-author:ScarfeAndrew... | lld:pubmed |
| pubmed-article:15507175 | pubmed:author | pubmed-author:SmylieMichael... | lld:pubmed |
| pubmed-article:15507175 | pubmed:author | pubmed-author:BodnarDianne... | lld:pubmed |
| pubmed-article:15507175 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15507175 | pubmed:volume | 5 | lld:pubmed |
| pubmed-article:15507175 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15507175 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15507175 | pubmed:pagination | 287-92 | lld:pubmed |
| pubmed-article:15507175 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:meshHeading | pubmed-meshheading:15507175... | lld:pubmed |
| pubmed-article:15507175 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15507175 | pubmed:articleTitle | Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. | lld:pubmed |
| pubmed-article:15507175 | pubmed:affiliation | Cross Cancer Institute, Universite de Montreal Canada. johnmack@cancerboard.ab.ca | lld:pubmed |
| pubmed-article:15507175 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15507175 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15507175 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:15507175 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
